Nirvana Life Sciences has announced it is making progress with its Health Canada Dealer’s licence application and its facility development.
Nirvana Life Sciences is researching and developing non-addictive pain management and relapse prevention products. Using naturally sourced psychedelics in novel formulations the company states it will be able to deliver solutions that are effective in managing pain and addiction.
The Canadian applied for a Dealer’s Licence from Health Canada in July 2021 which would permit research and development, manufacturing, import and export, sale to qualified investigators as well as sale to other Licensed Dealers in Canada for 29 different controlled substances.
The substances include novel compounds, consisting of different tryptamines, phenethylamines, ergolines and aryl cyclohexylamines.
Vice president of operations, Michael McCune, commented: “We are pleased with the steady progress that our team is making on licensing. The application for the 29 different controlled substances will support all the projects that Nirvana’s researchers have in the development pipeline.
“Our team’s focus on designing to the facility to the highest standard will ensure that our research and development projects meet the rigorous standards of Health Canada.”
As part of its review, Health Canada has requested further detail on volumes of materials to be handled and produced within the facility.
So far, the company has engaged three leading firms to support the projects development. These include CannDelta, a scientific and regulatory consulting company based in Toronto, Ontario; Stratus Designs, a control systems specialist based in BC; and Orion GMP Solutions, a pharmaceutical process engineering specialist based in Rochester, Michigan.
Nirvana has stated its team will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.
[activecampaign form=52]
